Chemistry Research

Medicilon's chemistry department comprises synthetic chemistry services and medicinal chemistry services. Clients can work with us on a Fee for Service or Full-Time Equivalent basis.

In 2021, Medicilon established the International Discovery Service Unit (IDSU). The IDSU provides global pharmaceutical companies with high-quality, efficient and cost-effective chemistry synthesis design and production, as well as medicinal chemistry. The IDSU supports the discovery and delivery of clinical candidate compounds for global drug research and development.

Download

Services

Medicilon Photochemistry Platform
Medicilon has been vigorously developing new technologies over the years, integrating emerging methods of green chemistry into its services, such as photoredox chemistry, electrochemistry, catalyst screening, continuous reactions, etc., to provide our customers with high-quality, cost-effective solutions.
Highly experienced in different types of photochemistry reactions Full capacity for synthesizing a variety of catalysts for photocatalytic reactions Strong expertise in photoredox chemistry

Service Models

At Medicilon, we offer a full range of chemical services covering all phases of your project. Customers can engage with us either through FFS or FTE.

Full-Time Equivalent (FTE)
Team composition: fixed team with team leaderIncludes analytical and logistic support
Fee For Service (FFS)
Clearly outlines labor costs, material costs, and project timeline

Technology Platform

Green Chemistry
Photochemistry platformMetal catalyst screening platformElectrochemical platformPhotoredox reaction

Drug R&D Service Platform

ADC Drug Discovery
Medicilon has over 50 Payloads，200⁺ Linkers，30⁺ Payload-Linker combinations. By the end of 2022, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, bispecific antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of the end of 2023, Medicilon has successfully assisted 24 ADC drugs to obtain clinical approval, and more than 20 ADC projects are in development.
PROTAC Drug Discovery
Medicilon has access to numerous popular POI ligands and various tissue types of E3 ligase ligands. Additionally, we have established a linker library containing hundreds of diverse molecules. By the end of June 2023, Medicilon had successfully assisted 5 PROTAC drugs in obtaining clinical approval, with over 20 PROTAC projects under development.
Nucleic Acid Drug Discovery
Medicilon’s nucleotide drug R&D platform provides a one-stop platform for monomer synthesis and modification; oligonucleotide synthesis; delivery system synthesis and oligonucleotide conjugate synthesis. The siRNA library constructed features a rich monomer inventory and a substantial monomer synthesis building block library to support the synthesis of various modified monomers.

Service Cases

pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use.webp

The Pan-FGFR1-4 irreversible inhibitor RG002 tablets were approved for clinical use

Learn More

SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use.webp

The anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical use

Learn More

ABM Therapeutics presented Medicilon with a commemorative trophy of our first candidate compound.webp

ABM Therapeutics presented Medicilon with a commemorative trophy for "our first candidate compound"

Learn More

For more service cases, please contact us:

Leave a message

Laboratory Instruments

The Chemistry department has more than 20,000 square meters of laboratory space and is equipped with advanced laboratory and analytical instruments:
NMRHPLCSFCUPLC-MSLC/MSDSCTGAICP-MS
The setup of our lab ensures that chemists can access all equipment and devices whenever needed.

Learn more about "Chemistry Research"